Atara Biotherapeutics, Inc. Stock

Equities

ATRA

US0465132068

Biotechnology & Medical Research

Market Closed - Nasdaq 16:00:00 2024-07-19 EDT 5-day change 1st Jan Change
11.01 USD +4.81% Intraday chart for Atara Biotherapeutics, Inc. +5.16% -14.12%
Sales 2024 * 111M 152M Sales 2025 * 67.39M 92.54M Capitalization 53.03M 72.82M
Net income 2024 * -89M -122M Net income 2025 * -119M -163M EV / Sales 2024 * 0.45 x
Net cash position 2024 * 3.5M 4.8M Net cash position 2025 * 61.53M 84.5M EV / Sales 2025 * -0.13 x
P/E ratio 2024 *
-0.65 x
P/E ratio 2025 *
-0.51 x
Employees 173
Yield 2024 *
454%
Yield 2025 *
454%
Free-Float 90.87%
More Fundamentals * Estimated data
Dynamic Chart
Atara Biotherapeutics Says Tab-Cel Biologics License Application Gets FDA Priority Review MT
Atara Biotherapeutics Announces U.S. Fda Acceptance and Priority Review of the Biologics License Application for Tabelecleucel (Tab-Cel®) for the Treatment of Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease CI
Transcript : Atara Biotherapeutics, Inc. Presents at Goldman Sachs 45th Annual Global Healthcare Conference, Jun-12-2024 09:20 AM
Sector Update: Health Care Stocks Ease Monday Afternoon MT
Atara Biotherapeutics Files Biologics License Application for Tabelecleucel with FDA; Shares Rise MT
Atara Biotherapeutics Submits Tabelecleucel (Tab-cel) Biologics License Application for Treatment of Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease with U.S. FDA CI
Earnings Flash (ATRA) ATARA BIOTHERAPEUTICS Reports Q1 Revenue $27.4M MT
Atara Biotherapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Stifel Adjusts Atara Biotherapeutics Price Target to $2.30 From $4.80, Maintains Hold Rating MT
Eric Dobmeier Not to Stand for Re-Election as Member of Board of Directors of Atara Biotherapeutics, Inc CI
Atara Biotherapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Earnings Flash (ATRA) ATARA BIOTHERAPEUTICS Reports Q4 Revenue $4.3M MT
Atara Biotherapeutics, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023 CI
North American Morning Briefing : Stocks Edge -2- DJ
North American Morning Briefing : Markets on Hold -2- DJ
More news
1 day+4.81%
1 week+5.16%
Current month+29.53%
1 month+23.71%
3 months-33.37%
6 months-30.65%
Current year-14.12%
More quotes
1 week
10.20
Extreme 10.2
12.98
1 month
7.07
Extreme 7.07
12.98
Current year
7.07
Extreme 7.07
39.50
1 year
4.97
Extreme 4.965
63.38
3 years
4.97
Extreme 4.965
501.00
5 years
4.97
Extreme 4.965
705.00
10 years
4.97
Extreme 4.965
1 639.00
More quotes
Managers TitleAgeSince
Chief Executive Officer 61 19-06-23
Director of Finance/CFO 49 17-12-31
Chief Tech/Sci/R&D Officer 51 21-05-09
Members of the board TitleAgeSince
Chairman 59 12-12-31
Director/Board Member 64 15-11-22
Director/Board Member 59 14-02-28
More insiders
Date Price Change Volume
24-07-19 11.01 +4.81% 22,318
24-07-18 10.5 -12.82% 79,751
24-07-17 12.05 -1.79% 120,211
24-07-16 12.27 +9.95% 77,383
24-07-15 11.16 +6.59% 44,059

Delayed Quote Nasdaq, July 19, 2024 at 04:00 pm

More quotes
Atara Biotherapeutics, Inc. is an allogeneic T-cell immunotherapy company. The Company is a developer of T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with serious diseases, including solid tumors, hematologic cancers, and autoimmune diseases. Its pipeline products include Ebvallo (Tab-cel), ATA3219. The Company’s T-cell immunotherapy, tab-cel (tabelecleucel), is in Phase III development for patients with EBV-driven post-transplant lymphoproliferative disease (EBV+ PTLD) who have failed rituximab or rituximab plus chemotherapy, as well as other EBV-driven diseases. Its ATA3219 is in Phase 1 development is being developed as a potential product intended to target B-cell malignancies and autoimmune diseases, based on a next generation 1XX co-stimulatory domain and the innate advantages of EBV T cells as the foundation for an allogeneic CAR T platform.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B-
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
7
Last Close Price
11.01 USD
Average target price
104 USD
Spread / Average Target
+844.60%
Consensus